
Loading, please wait...

Loading, please wait...

Capturing specific proteins from complex biological samples remains a significant challenge in medical research. Researchers recently made a major advancement in lysozyme capture technology by developing a hierarchical three-dimensional polymeric nanofibrous aerogel. This innovative scaffold allows for high-capacity and ultraselective capture of lysozymes.
The research team utilized 3-Aminophenylboronic acid (APBA) as a functional monomer. This monomer creates multimodal interaction sites that are essential for recognizing lysozyme. Consequently, the synergy of electrostatic interactions, hydrophobic forces, and π-π stacking leads to superior performance. Specifically, the aerogel achieved an adsorption capacity of 736.90 mg/g. This value significantly exceeds existing state-of-the-art adsorbents. Furthermore, the selectivity coefficient reached an impressive 4.17.
Practical utility was demonstrated through the extraction of lysozymes from raw egg white. Importantly, the process preserves the native conformational integrity of the enzyme. As a result, the extracted lysozymes exhibited potent antibacterial activity against Staphylococcus aureus. This finding is crucial because it confirms that the capture method does not compromise the protein's therapeutic potential. Additionally, molecular simulation methods verified the interaction mechanism at the interface of the imprinted polymers.
Overall, this research provides a feasible idea for designing highly selective adsorbents. Such advancements in protein separation could streamline the production of bioactive enzymes for clinical applications. Moreover, the study illustrates the power of multimodal interactions in molecular imprinting.
The aerogel uses a three-dimensional scaffold and multimodal interactions, such as electrostatic and hydrophobic forces, to achieve much higher capacity and selectivity than traditional materials.
No, the study confirms that the extracted lysozyme maintains its full antibacterial potency against Staphylococcus aureus and its native structural shape.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or professional services. Always consult a qualified healthcare provider for medical concerns. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Researchers have engineered a 3D polymeric nanofibrous aerogel for highly selective lysozyme capture. Achieving an adsorption capacity of 736.90 mg/g, this technology preserves the enzyme's antibacterial potency against S. aureus, offering a major advancement in protein separation for pharmaceutical use.
4 months ago

A breakthrough study evaluated H5N1 transmission efficiency across mammalian isolates. Researchers discovered that human-derived D1.1 harboring the PB2 D701N mutation spread efficiently in ferrets, unlike strains carrying PB2 E627K. This finding highlights critical genetic markers for zoonotic surveillance.
Today

A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today